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Abstract
Aims/hypothesis Variants in the TCF7L2 gene remain the
strongest genetic associations with increased risk of type 2
diabetes. Recently, we identified a unique splicing form of
TCF7L2 expressed in pancreatic islets, pancreas and colon
and detected by assay ‘ex13-13b’. The expression of ex13-13b
strongly correlated with proinsulin in glucose-stimulated
pancreatic islets, suggesting a potential role for this form in
the development of type 2 diabetes. The goal of this study was
to further characterise this unique TCF7L2 splicing form in
human tissues.
Methods We used a panel of 34 human tissues and 80
human cell lines to measure the expression of assay ex13-
13b with use of quantitative RT-PCR.
Results The highest expression of assay ex13-13b was
detected in several areas of the brain (hypothalamus/
thalamus, occipital lobe) and in neuronal cell line SHS5Y5.
Low expression was confirmed in pancreatic islets, small
intestine, pancreas and colon, while no expression was
detected in other human tissues and cell lines. The
expression of assay ex13-13b correlated with the gene for
cocaine- and amphetamine-regulated transcript (CART, also
known as CARTPT) in a panel of human tissues (n=12,
r=0.85, p=0.00046), pancreatic islets (n=23, r=0.62,
p=0.0016) and colon (n=98, r=0.54, p<0.0001).
Conclusions/interpretation The significant correlation be-
tween expression of a unique splicing form of TCF7L2,
named here TCF7L2-NE, and CART, the gene for an
anorexigenic neurohormone expressed in the central and
peripheral nervous system, suggests that these transcripts
may share neuroendocrine functions important for brain,
gut and pancreatic islets.
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Abbreviations
TCF7L2 Transcription factor 7-like 2
TCF7L2-NE Neuroendocrine splicing form of TCF7L2
Introduction
Transcription factor 7-like 2 (TCF7L2) (also known as
TCF-4) plays a central role in the WNT pathway and is
involved in a variety of biological processes. Non-coding
genetic variants within TCF7L2 gene remain the strongest
genetic association with increased risk of type 2 diabetes
and dysfunction of pancreatic islets [1, 2]. However, the
molecular and cellular mechanisms through which TCF7L2
contributes to these associations are still unclear.
Previously,wedescribedatissue-specificsplicingdiversity
of the gene resulting from the use of three alternative
promotersandsixalternative exons [3]. We detected a unique
splicing form defined by the presence of an alternative
C-terminal exon, 13b, expressed in pancreatic islets, colon
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with insulin expression in glucose-stimulated pancreatic
islets and was decreased in islets of carriers of the type 2
diabetes-associated single nucleotide polymorphisms of
TCF7L2, rs7903146 and rs12255372 [3].
In the current study we aimed to further characterise the
TCF7L2 splicing form containing the alternative exon 13b.
We provide evidence for a neuroendocrine pattern of
expression of this form, named TCF7L2-NE,i nh u m a n
tissues and cell lines. We show that expression of TCF7L2-
NE correlated with expression of the gene for cocaine- and
amphetamine-regulated transcript (CART,a l s ok n o w na s
CARTPT), also found in the brain, islets and gut. CART
has been shown to play a critical role in glucose sensing,
stimulation of hormone secretion, cell survival, thermoreg-
ulation and appetite suppression. Based on strong correlation
between expression of TCF7L2-NE and CART in a panel of
human tissues, islets and colon, these data suggest that
TCF7L2-NE may have important neuroendocrine functions.
Methods
Samples, cDNA preparation and expression analysis Sam-
ples of total RNA from human tissues were purchased from
Clontech (Mountain View, CA, USA) and BioChain Institute
(Hayward, CA, USA). Samples of human pancreatic islets,
monocytes, colon, pancreas and lymphoblastoid cell lines
were previously described [3]. RNA from the NCI-60 cell
lines was provided by the Molecular Targets Team, Devel-
opmental Therapeutics Program, Division of Cancer Treat-
ment and Diagnosis, NCI/NIH. All other cell lines were
purchased from ATCC (Manassas, VA, USA) or Asterand
(Detroit, MI, USA). Total RNAwas prepared with a MirVana
kit (Ambion, Austin, TX, USA) and the quality was
evaluated with a Bioanalyzer 2100 (Agilent, Santa Clara,
CA, USA). cDNA from all samples was prepared from 1 μg
total RNA, as previously described [3]. All reactions were
run in duplicate in 5 μl volumes in 384-well optical plates on
an SDS7900 (Applied Biosystems, Foster City, CA, USA).
Negative controls and genomic DNA controls were used for
all assays. The expression of endogenous control genes, beta-
2m i c r o g l o b u l i n( B2M) and cyclophilin A (PPIA), measured
in separate reactions but in the same cDNA samples was used
for normalisation of expression. All assays were tested before
analysis and showed comparable amplification efficiencies.
The list of expression assays is provided in the Electronic
supplementary material (ESM) Table 1.
Statistical analysis Average values for technical duplicates
were normalised by geometric means of endogenous
controls according to the ΔCt method of relative quantifi-
cation, as previously described [3]. Pearson’s correlation
coefficients and two-sided p values were calculated with
SPSS 16.0 software (SPSS, Chicago, IL, USA). p values
were not adjusted for multiple tests.
Results
Expression of the TCF7L2 splicing form with exon 13b in
human tissues and cell lines Initially, the expression of
TCF7L2 assay ex13-13b was detected in pancreatic islets,
pancreas and colon [3]. We then tested the expression of
this assay in 34 human tissues and 80 cell lines (60 cell
lines from the NCI-60 set and 20 additional cell lines; ESM
Tables 2 and 3). High expression of assay ex13-13b was
detected in several areas of the brain (thalamus, hypothal-
amus, occipital lobe) and in SHS5Y5 neuroblastoma cell
line, but not in other brain-derived cell lines (a human
neuronal epithelioma cell line SK-N-MC and glioblastoma
and astrocytoma cell lines SF_268, SF_295, SF_539,
SNB_19, U251 and SNB_75). Expression was also detected
inpancreaticislets,smallintestine,colonandpancreas,butnot
in other human tissues, NCI-60 and additional cell lines
(Table 1). We PCR amplified a fragment of TCF7L2 gene
between a constitutive exon 10 and an alternative exon 13b
in cDNA from human brain and pancreatic islets (Fig. 1a,b).
There were four possible combinations of alternative exons
12, 13, 13a and 13b in splicing forms with exon 13b. The
splicing forms that include both exons 13a and 13b have two
alternative stop codons separated by 37 bp (Fig. 1a,b).
Expression of these forms (assay 13a-13b) was found to be
very low in brain and islets and was not studied further
(data not shown). However, the expression of assay ex13-
13b was up to 750 times higher in the brain than in
pancreas (Table 1).
Coexpression of TCF7L2 assay ex13-13b with brain–islet–
gut neurohormones The pattern of expression of TCF7L2
splicing form detected by assay ex13-13b suggested that it
might be expressed in neuroendocrine cells of brain, islets
and gut. Based on the literature, we selected a number of
neurohormones that can be expressed in the brain and
enteric nervous system [4]. We tested for correlation in
expression of assay ex13-13b with several neurohormone
genes, neuropeptide Y (NPY) and agouti-related peptide
(AGRP) expressed in glucose-inhibited neurons, pro-
opiomelanocortin (POMC)a n dCART expressed in
glucose-activated neurons, a marker of endocrine function
chromogranin A (CHRA, also known as CHGA), and
several other neuropeptides: ghrelin (GHRE, also known
as GHRL), vasoactive intestinal peptide (VIP), gastric
inhibitory polypeptide, also known as glucose-dependent
insulinotropic peptide (GIP) and somatostatin (SST).
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and 20 additional cell lines) the most similar pattern of
tissue distribution and level of expression was observed
between TCF7L2 assay ex13-13b and CART (r=0.85, p=
0.00046, Table 1). Both these transcripts were expressed
highly in the brain and in neuronal cell line SHS5Y5, low
in small intestine, islets, colon and pancreas and not
expressed in all other tissues and cell lines tested, even
though the expression of endogenous controls B2M and
PPIA was equally high in all these samples (data not
shown). Based on the observed pattern of expression, we
designated the splicing form detected by assay ex13-13b as
a neuroendocrine splicing form, TCF7L2-NE. Expression of
TCF7L2-NE also showed correlation with CART in human
pancreatic islets (n=23, r=0.62, p=0.0016) and colon (n=98,
r=0.54, p<0.0001). Expression of both TCF7L2-NE and
CART in pancreas (n=44) was low and not detectable in all
samples and was not analysed (data not shown).
The protein encoded by this splicing form is
C-terminally truncated and lacks binding sites for the
C-terminal binding protein (CtBP) that regulates TCF7L2
post-translationally [5]. Alternative exon 13b contributes
only two amino acids before the termination of transcrip-
tion, making it impossible to distinguish TCF7L2-NE from
other TCF7L2 forms at the protein level. We tested cellular
localisation of this form by transfecting an expression
construct for the full-length TCF7L2-NE splicing form
(GenBank FJ010169) [3] into human PANC-1 cells. The
localisation of this form was clearly nuclear (Fig. 1c), as
was expected based on the presence of nuclear localisation
signals and the role of TCF7L2 as a transcription factor.
Discussion
Disturbances in brain–gut–islet regulation of satiety and
glucose metabolism are associated with development of
obesity and type 2 diabetes [6, 7]. In this study we provide
evidence that the unique splicing form of TCF7L2 that we
named a ‘neuroendocrine form, TCF7L2-NE’, might be a
part of this regulation. TCF7L2-NE exhibits a neuronal
pattern of expression, as it is highly expressed in the
Table 1 Expression of TCF7L2 assay ex13-13b and neurohormone genes
Tissue TCF7L2
ex13-13b
ex13-13b
(fold vs
pancreas)
CART CHRA NPY GHRE VIP AGRP SST POMC GIP
Thalamus −4.25 750 −6.13 −4.50 −2.67 −12.83 −8.58 −14.49 −4.55 ND ND
Occipital lobe −5.42 333 −5.15 −0.23 −1.00 −10.97 −2.80 −12.75 −0.86 ND ND
Hypothalamus −6.49 159 −6.06 −5.57 −3.98 −13.39 −8.58 ND −2.94 ND ND
Cerebellum −7.82 63 −5.13 −6.53 −8.85 −12.74 −8.64 −11.73 −14.85 ND ND
Pituitary gland −8.58 37 −9.15 −0.33 ND −13.76 −14.13 ND −10.74 ND ND
SHS5Y5
neuroblastoma
cell line
−8.75 33 −10.50 NT NT NT NT NT NT NT NT
Hippocampus −8.99 28 −6.57 −3.51 −3.85 −10.85 −6.68 −13.05 −5.54 ND −14.76
Small intestine −11.36 5.4 −9.49 −3.83 −7.02 −9.26 −7.01 ND −5.83 ND −6.91
Pancreatic islets −11.84 3.9 −12.05 0.76 −3.14 −5.79 −11.48 −16.50 3.29 −13.18 ND
Colon tumour −13.24 1.5 −10.90 −9.47 ND ND −8.13 ND −14.09 ND ND
Colon −13.84 1.2 −10.77 −6.04 −10.98 ND −6.80 ND −8.14 ND ND
Pancreas −13.80 1.0 −11.95 −3.31 −7.27 −11.12 −7.62 ND −2.59 ND ND
Correlation (r) – 0.85 0.21 0.66 −0.57 0.10 0.45 0.11 NS NS
p value 0.00046* NS 0.06 NS NS NS NS
Expression values are normalised to endogenous controls B2M and PPIA. Pearson’s correlation coefficients (r) are for expression of TCF7L2
assay ex13-13b and each neurohormone
Each tissue is represented by one sample or a pool of samples from two or three individuals; expression of assay ex13-13b was not detected in the
following tissues: liver, lung, spleen, kidney, skeletal muscle, heart, blood, monocytes, lymphoblasts, breast, parotid, thyroid, ovary, oesophagus,
stomach, bladder, prostate, ovarian cancer, lung cancer, kidney cancer, breast cancer, adipose and in NCI-60 cell lines and additional cell lines
293T, HepG2, HeLa, MDA435, MCF10, PANC1, SK-N-MC, prostate cell lines OPCN1, OPCN2, OPCN3, OPCT1, OPCT2, OPCT3, RWPE-1,
RWPE-2, PWR1E, bladder cancer cell lines HTB-5, HTB-9, HT-1376 and J-82
*p value will be significant even after adjustment for multiple tests
ND, expression tested but not detected; NS, no significant correlation based on samples with detectable expression for both assays; NT, expression
not tested
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well as in a neuronal cell line SHS5Y5. Comparatively lower
levels of expression were found in islets and gut (up to 750-
fold lower than in brain), while no expression was found in
all other human tissues and cell lines tested here. Expression
of a similar murine splicing form of TCF7L2 (designated as
a form with exons 12-13-14-17-18) was recently located to
postmitotic neurons of mouse midbrain [8].
TCF7L2-NE is highly expressed in the brain areas that
contain neurons of the hypothalamic arcuate (ARC) nucleus
that regulate energy metabolism and satiety. Glucose-sensing
neuronsexpressCARTand POMC [4]. In the panel of human
tissues used in this study, expression of TCF7L2-NE
correlated with CART but not with POMC, possibly marking
a subpopulation of glucose-activated neurons activated by
blood glucose, insulin and leptin [9]. Expression of TCF7L2-
NE did not correlate with NPY and AGRP (markers of
glucose-inhibited neurons activated by ghrelin and inhibited
by glucose and leptin [4]). In sum, expression of TCF7L2-
NE and CARTstrongly correlated in a panel of human tissues
Thalamus
Occipital lobe
Cerebellum
Pancreatic islets
Form A. ex10-11-13-13b, 199 bp
Form D. ex10-11-12-13-13a-13b, 323 bp
Form B. ex10-11-12-13-13b, 250 bp
Form C. ex10-11-13-13a-13b, 272 bp
100 bp marker
ex10 ex11 ex12 ex13 ex13a ex13b
ex10 ex11 ex13 ex13b
ex10 ex11 ex12 ex13 ex13b
ex10 ex11 ex13 ex13a ex13b
ex10 ex11 ex12 ex13 ex13a ex13b 323 bp
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Fig. 1 C-terminal alternative exons of TCF7L2 in transcripts expressed in
total human brain and pancreatic islets and cellular localisation of
TCF7L2s p l i c i n gf o r md e t e c t e db ya s s a ye x 1 3 - 1 3 b( TCF7L2-NE). a
Results of PCR amplification with primers ex10 Forw and ex13b Rev of
TCF7L2 (ESM Table 1) in cDNA from human brain and pancreatic
islets. cDNA prepared from 10 ng total RNA was used for all PCR
reactions. The PCRs were performed with Phusion DNA polymerase
(New England Biolabs, Ipswich, MA, USA) and the PCR products were
resolved on a 2% (wt/vol.) agarose gel. Four types of PCR fragments
(forms A–D) were observed based on the combination of alternative
exons 12, 13, 13a and 13b. b Schematic representation of C-terminal
exons of TCF7L2. Constitutive exons are represented by black rectangles
and alternative exons by white rectangles. Black triangles mark alternative
translation stops. Arrows indicate positions of PCR primers. Forms A and
B use a stop codon within exon 13b and forms C and D use a stop codon
within exon 13a. In the forms with alternative exons 13a and 13b (C and
D) two in-frame stop codons are separated only by 37 bp. Expression of
these forms (assay ex13a-13b) was very low in brain and islets and was
not studied further. c Two confocal images showing cellular localisation of
the recombinant TCF7L2-NE in human PANC-1 cell line (pancreatic
cancer). Panels represent images of PANC-1 cells transfected with the
TCF7L2-NE Halo-tag expression construct (GenBank FJ010169) [3].
Non-transfected cells serve as controls for specificity of detection. For the
expression construct a full-length cDNA for TCF7L2-NE splicing form
was cloned into a pFC8A expression vector with a C-terminal Halo-tag
(Promega, Madison, WI, USA). The endotoxin-free plasmid was prepared
with a EndoFree plasmid Maxi kit (Qiagen, Gaithersburg, MD, USA). For
transfection, human PANC-1 (pancreatic cancer) cells were plated on
chamber slides (Thermo Fisher Scientific, Rochester, NY, USA) and
transfected next day with Lipofectamine 2000 reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s instructions. After
48 h, the cells were fixed and incubated with primary rabbit anti-HaloTag
antibodies (Promega) and with mouse anti-α-tubulin antibodies ab7291-
100 (Abcam, Cambridge, MA, USA). Secondary donkey anti-rabbit and
anti-mouse antibodies labelled with Alexa fluor 594 and 488 were used
for imaging (Invitrogen). The anti-fade ProLong Gold mounting media
with DAPI (Invitrogen) was used to mount the cover slides. The imaging
was performed with a confocal microscope LSM 510 Meta (Carl Zeiss
Microimaging, Thornwood, NY, USA) with ×63 magnification
Diabetologia (2010) 53:712–716 715(n=12, r=0.85, p=0.00046), in islets (n=23, r=0.62, p=
0.0016) and colon (n=98, r=0.54, p<0.0001) with p values
being significant even after adjustment for multiple tests.
CART has been shown to play a critical role in glucose
sensing, stimulation of hormone secretion in pancreatic islets,
neuronal survival, thermoregulation and appetite suppression
[4, 10, 11]. The functional relationship between TCF7L2-NE
and CART is not clear. Based on the strong correlation
between expression of TCF7L2-NE and CART,w es u g g e s t
that these transcripts may have similar functions related to
the brain–islet–gut regulation of metabolism. Further studies
will be needed to identify the functional role of TCF7L2-NE
in different metabolic conditions.
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